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ABSTRACT  
Background:  
Abdominal aortic aneurysm (AAA) is a dilatation of the abdominal aorta, which is usually 
asymptomatic.  However, rupture of the aneurysm can be fatal or require complex surgery with 
potential complications, leading to a poor quality of life.  Patient reported outcome measures 
(PROMs) are becoming increasingly important in the current era of healthcare management. PROMs 
are used to directly assess how patients feel or function in relation to their health condition without 
any interpretation.   Generic, disease-specific and preference-based PROMs can be used to assess 
the quality of life (QoL), symptoms and functional limitations in patients with AAA including those 
under surveillance or undergoing endovascular or open surgery or screening.  However, these tools 
vary in terms of their reliability, validity and suitability for use in patients with AAA in a clinical 
setting. 
 
Objectives:  
To identify, summarise and assess PROMs that have been administered to patients with a diagnosis 
of AAA including those under surveillance or undergoing endovascular or open surgery or screening. 
Methods:   
Key electronic databases and research registers will be searched including: MEDLINE and MEDLINE in 
Process, EMBASE, PsycINFO, PROQOLID, CINAHL, PROMS Bibliography (Oxford University), Web of 
Science and the Cochrane Library databases from inception.  A two-stage search approach will be 
used. The first stage will utilise general terms for PROMs to identify studies.  These will be retrieved 
and the title and abstract will be examined for additional PROM terms.  Stage 2 will incorporate 
these terms with the preliminary search strategy and a methodological search filter.  Searches will 
be supplemented by hand-searching reference lists of relevant reviews and included studies.  Study 
selection, data extraction and quality assessment will be performed independently by at least 2 
reviewers.   All English language instruments identified as PROMs for patients with AAA will be 
included.  Data will be extracted regarding type of PROM, methods and results. Methodological 
quality of included studies will be assessed using the COnsensus-based Standards for the selection of 
health status Measurement INstruments checklist (COSMIN) and the psychometric properties of the 
PROMs will be assessed on criteria based in published recommendations.  Findings will be presented 
as narrative and tabular summaries. 
Discussion: 
This systematic review will identify PROMs that are used to assess QoL, symptoms and functional 
limitations in patients with AAA and assess their effectiveness for this population and application to 
clinical practice.  The findings of the review will help inform a project examining the re-configuration 
of vascular services in the UK, and identify targets for future research. 
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Background 
Abdominal aortic aneurysm (AAA) is a dilatation of the abdominal aorta, which is usually 
asymptomatic. However, some people may develop pain or a pulsating feeling in their abdomen or 
persistent back pain.  Larger aneurysms (> 55mm) are at an increased risk of rupture resulting in 
massive internal bleeding and an extremely high mortality rate or complications resulting in poor 
quality of life.[1]  Around 8 out of 10 people with a rupture either die before they reach hospital or 
do not survive surgery.  The risk of AAA increases significantly after the age of 60 [2]  and men are 
four to six times more likely than women to develop  AAA.[3]  However, women can also be at risk, 
particularly those with a history of smoking or heart disease.  The prevalence of AAAs is estimated at 
1.3-12.7% in the UK [4]but has been declining since 2000.[5] Depending on the size of the aneurysm, 
the main treatment options for patients with AAA are surgical procedures (open repair or 
endovascular repair) or monitoring, with better treatment outcomes in those with early detection of 
the disease.  As patients with AAA are mostly asymptomatic screening programmes are very 
important in reducing the mortality and morbidly rate.  
Patient reported outcome measures (PROMs) relating to symptoms, functional or health related 
quality of life (HRQoL) are obtained directly from the patient. These outcomes can be used to obtain 
information about morbidity and ‘patient suffering’, and can be used to assess the quality of life 
(QoL) of patients.  PROMs are valued by patients, clinicians, and policy-makers as they provide 
information that supplement clinical outcomes and help to inform disease management practices, 
therapeutic choices, reimbursement decisions, and health policy.  The current evidence regarding 
those PROMs used to assess the QoL of patients with AAA (including those under surveillance or 
undergoing endovascular or open surgery or screening) in a clinical setting is equivocal, in terms of 
their reliability, validity and suitability for use. 
 
 
Aims and Objectives 
The aim of this review is to (i) systematically identify PROMs that have been administered to 
patients with AAA (ii) to identify PROMs which have been validated in patients with AAA (iii) to 
evaluate the psychometric properties of PROMs which have been validated in this patient group 
using the COnsensus-based Standards for the selection of health status Measurement INstruments 
(COSMIN) [6](iv) and using the findings to inform the development of the Electronic Patient 
Assessment Questionnaire-Vascular(ePAQ-VAS) system for use in vascular services. 
 
Methods 
This systematic review will be conducted and reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[7] 
Literature searching 
Key electronic databases and research registers will be searched including MEDLINE and MEDLINE in 
Process, EMBASE, PsycINFO, PROQOLID, CINAHL, PROMS Bibliography (Oxford University), Web of 
Science and the Cochrane Library databases from their dates of inception.  A two-stage search 
approach will be used. The first stage will utilise terms for PROMs, QoL and abdominal aortic 
aneurysm to identify studies reporting PROMs in patients with AAA. These will be retrieved and the 
title and abstract examined for additional PROM terms. Stage 2 will incorporate these terms with the 
preliminary search strategy and a methodological search filter for finding studies on measurement 
properties.[8] The search strategy will be developed by an experienced information specialist in 
consultation with methodological and topic experts, if necessary, the search strategy will be adapted 
within different databases.  No language or date restriction will be applied. Searches will be 
supplemented by hand-searching reference lists of included studies, relevant reviews and citation 
searches. All retrieved records will be imported and managed within a reference management 
database. 
Eligibility criteria 
Published or unpublished full-text journal articles including structured abstracts evaluating the use 
or validation of PROMs capturing QoL, health status or functional limitation in patients with AAA will 
be considered.  The population of interest are patients with a diagnosis of AAA undergoing any 
treatment (medical or surgical) for AAA including screening.  No date restriction will be applied but 
only studies published in English language will be included.  In addition, studies that are published in 
English that report non-English translations of relevant PROM instruments or PROMs elicited from 
non-English speakers will be excluded.  The outcomes of interest are PROMs (including generic, 
disease-specific, preference-based, functional and symptom-based) used in patients with AAA 
(including those under surveillance or undergoing endovascular or open surgery or screening).   
Study selection  
At least two reviewers will screen all references according to the agreed pre-specified eligibility 
criteria (see Table 1). After sifting of titles and abstracts from both searches, all full-text articles of 
potentially relevant studies from the retrieved records will be obtained for detailed examination. 
Ineligible studies will be excluded and the reason for rejection will be recorded.  Disagreements 
between the two reviewers will be resolved by discussion, with the involvement of a third reviewer 
where agreement cannot be reached. The PRISMA template will be used to produce a flow chart 
showing details of studies included and excluded at each stage of the study selection process. 
 
 
 
 
 
 
 
 
Table 1:  Eligibility criteria 
Inclusion criteria Exclusion criteria 
 
Type of participants 
A defined population of participants with a 
diagnosis of AAA  
 
Unspecified population of AAA patients 
Patients with pseudoaneurysms 
Patients with thoracic aortic aneurysms, 
involving the aortic root, ascending aorta, 
aortic arch or descending aorta. 
Patients with thoracoabdominal aneurysms 
 
Type of intervention 
Screening  
Any Treatment: Emergency, elective or supportive 
treatment including 
open surgery, endovascular aneurysm repair, 
medical treatment 
 
 
Type of outcomes 
PROMs obtained using any of the following 
methods: 
 
- generic preference-based measures e.g. 
EQ-5D, SF-36 
Outcome measures of patient satisfaction 
or experience in the relevant population 
- directly elicited preference-based 
measures e.g. TTO, SG utility values 
Non-English versions of relevant PROMs 
- condition-specific outcome measures PROMs elicited from non-English speakers 
- functional limitations or symptom-based 
measures 
 
- English version of PROMs  
 
Type of study 
Published or unpublished peer reviewed journal 
articles including full-text or structured abstract  
Reviews, Editorial and Opinion pieces 
 
 
  
Language 
English Non-English 
Abbreviations: AAA, abdominal aortic aneurysm; EQ-5D,  European quality of life questionnaire -5 
dimension; PROMs, patient reported outcome measures; SF-36, Medical Outcomes Study 36-item short 
form Health Survey; SG, standard gamble; TTO time-trade-off. 
 
 
Data collection process 
Two reviewers will independently extract data from the studies using a specifically designed data 
extraction form. The form will be piloted on a sample of two randomly selected studies and then 
altered if required before full data extraction begins. Discrepancies will be resolved by discussion, 
with the involvement of a third reviewer where necessary. Authors will be contacted in order to 
obtain any missing data. In the case of double publication of the same study, data will be combined 
as a single study.    
 
Data items 
Data extraction will be undertaken in two stages. The first stage will involve abstracting data from all 
included studies and will aim to identify all PROMs used in patients with AAA. From the abstracted 
data two sets of studies will be identified:  
(1) SET 1 studies: Studies reporting PROMs (generic, disease-specific, both preference based and 
non-preference based measures, functional limitations and symptoms) in patients with AAA.  
(2) SET 2 studies: Studies reporting on the development and/ or validation of PROMs – to assess 
suitability of the PROM(s) for clinical/research use.  
In the first stage general information regarding, study characteristic, population characteristic and 
outcome measures will be extracted, including the aim of the study, details on whether the study 
addresses the  development and/or validation of a PROMs, treatment strategy and type of outcome  
measures used. 
In the second stage, a more in-depth data extraction will be undertaken for studies in SET 2, to help 
evaluate the psychometric performance of reported outcome measures.   Data will be extracted to 
assess the quality of the studies, identify the likely areas of quality of life affected by the condition 
and assess the overall performance of the outcome measures; for example regarding type of 
instrument, sample, number of items and domains, suitability of the tool for the condition, including 
practicality, sensitivity and validity. 
Quality assessment:  
Two researchers will independently assess the methodological quality of the included studies against 
the COSMIN checklist [6]and using the criteria in Table 2 for assessing the performance and 
psychometric properties of the validated PROMs identified. Any discrepancies will be resolved by 
consensus and if necessary a third reviewer will be consulted.  
 
 
 
 
 
 
 
 
Table 2: Appraisal criteria for assessing the psychometric properties of patient reported outcome 
measures 
Domain Criteria 
Test re-test 
 
The intra-class correlation/ weighted kappa score should be ≥0.70 for group 
comparisons and ≥ 0.90 if scores are going to be used for decisions about an individual 
based on their score. [6] 
  
The mean difference (paired t test or Wilcoxon signed-rank test) between time point 1 
(T1) and time point 2 (T2) and the 95% CI should also be reported. 
Internal consistency 
 
A Cronbach’s alpha score of ≥0.70 is considered good and it should not exceed ≥0.92 for 
group comparisons as this is taken to indicate that items in the scale could be 
redundant.  Item total correlations should be ≥0.20.[9]  
Content validity 
 
This is assessed qualitatively during the development of an instrument. To achieve good 
content validity, there must be evidence that the instrument has been developed by 
consulting patients, experts as well as undertaking a literature review.  
 
Patients should be involved in the development stage and item generation. The opinion 
of patient representatives should be sought on the constructed scale.[6;9;10] 
Construct validity A correlation co-efficient of ≥0.60 is taken as strong evidence of construct validity. 
Authors should make specific directional hypotheses and estimate the strength of 
correlation before testing.[6;10;11] 
Criterion validity 
 
A good argument should be made as to why an instrument is a gold standard and 
correlation with the gold standard should be ≥ 0.70.[11] 
Responsiveness 
 
There are a number of methods to measure this including t-tests, effect size, 
standardised response means or responsiveness statistics Guyatts’ responsiveness 
index. There should be statistically significant changes in score of an expected 
magnitude.[12] 
Floor-ceiling effects  A floor or celling effect is considered if 15% of respondents are achieving the lowest or 
the highest score on the instrument.[11] 
Acceptability  
 
Acceptability was measured by the completeness of the data supplied. 80% or more of 
the data should be complete.[10] 
 
Strategy for data synthesis 
The psychometric properties of the PROMs identified will be described and evaluated using a set of 
standardised criteria taken from a number of published studies.[6;9-12]   From the findings, PROMs, 
if any, that are ready for clinical use or which need further work will be highlighted and discussed. 
For studies that do not report development or validation of PROMs in AAA, a tabular narrative 
synthesis will be undertaken, structured around the type of PROM identified (generic, disease-
specific, preference based, functional, symptom), the domains each PROM measured, characteristics 
of participants and treatment strategy. 
 
 
 
 
 
Discussion 
PROMs are a valuable tool to clinicians and decision makers to guide them in providing an efficient 
and cost-effective treatment plan for patients.  To date there has been no systematic reviews 
reporting PROMs that have been used to assess QoL, symptoms or functional limitations in patients 
with AAA. It is unclear regarding the evidence for the validity of PROMs in this patient population or 
evaluated their suitability for use in this group.  We plan to use a systematic approach with a 
comprehensive search strategy to identify PROMs that have been used in patients with AAA 
(including those under surveillance or undergoing endovascular or open surgery or screening), and 
assess its psychometric properties and suitability for use in this population. 
Strengths and limitations 
The strength of our review lies on the comprehensive two step search strategy which will be used to 
identify studies.  The search strategy will be developed by an experienced information specialist in 
conjunction with a multi-disciplinary team of clinical and methodological experts.   In addition two 
reviewers will undertake the screening, data coding and data extraction of all the studies.   Our 
results may be limited due to the decision to exclude studies published in non-English language, non-
English version of relevant PROMs and PROMs elicited from non-English speakers.  However as this 
review is undertaken to inform a project[13] examining the re-configuration of the vascular services 
in the UK, it is vital for the evidence base to reflect its users. 
Relevance of the review 
The findings of this review will enable us to identify PROMs which are or are not appropriate for 
clinical use in patients with AAA (including those under surveillance or undergoing endovascular or 
open surgery)  within the  vascular services in the UK, and  highlight the gap in the evidence base for 
further research.  Furthermore, findings from this review will be supplemented by qualitative 
evidence to inform the development of ePAQ-VAS system for use in vascular services.  
 
Dissemination plans 
We will disseminate our findings in a report to the NIHR, conferences proceedings and peer-
reviewed journal publications. 
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